Accuray Inc is a leading innovator in cancer treatment technologies, primarily focusing on advanced radiation therapy solutions. The company specializes in the development of systems that deliver precise and targeted radiation to tumors, aiming to maximize therapeutic efficacy while minimizing damage to surrounding healthy tissue. Accuray's flagship products, including the CyberKnife and TomoTherapy systems, are designed to improve patient outcomes through increased accuracy and flexibility in treatment planning. Through its commitment to innovative engineering and clinical excellence, Accuray plays a significant role in enhancing the landscape of cancer care. Read More
Dallas TX - Sept. 28, 2026 - VivoSim Labs Inc. (NASDAQ: VIVS) is developing human-relevant testing technologies designed to identify unsuccessful drug candidates earlier, potentially improving the economics of pharmaceutical development.
Dallas TX - Sept. 28, 2026 - American Fusion Inc. (OTCQB: AMFN) has filed 21 additional U.S. patent applications, bringing its Texatron™ intellectual-property portfolio to 151 pending U.S. applications, as the company continues testing its fusion-energy platform and prepares for a potential national-exchange listing.
Accuray (NASDAQ:ARAY) released fourth-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
The global absorbable hydrogel tissue spacer market, used primarily in prostate cancer radiation therapy , is gaining momentum as healthcare providers increasingly adopt technologies designed to reduce treatment side effects while improving patient outcomes.
Medical technology, infection control systems, oncology radiotherapy solutions, and diagnostics innovation remain key healthcare growth themes heading into 2026—and CS Diagnostics Corp. (OTCQB: CSDX) is positioning itself at the intersection of both.
San Francisco, CA – October 3, 2025 – In a move set to redefine the landscape of radiation oncology, Leo Cancer Care officially introduced its groundbreaking Upright Photon Therapy System, "Grace," at the ASTRO 2025 meeting in San Francisco on September 28, 2025. This innovative system challenges decades of conventional practice by
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed
